Jeffrey Cleland

Jeffrey L. Cleland, Ph.D., is a prominent figure in the biotechnology sector, currently serving as a Board Member at Elixirgen Therapeutics, Inc. He was appointed to this position on December 21, 2022, to aid the company in advancing its controllable self-replicating RNA (c-srRNA) platform for developing therapies targeting various diseases, including rare and aging-related disorders as well as cancer.14

Educational Background

Dr. Cleland holds a Doctor of Philosophy degree in Chemical Engineering and a Bachelor of Science in the same field.2

Professional Experience

In addition to his role at Elixirgen Therapeutics, Dr. Cleland is the Executive Chairman, President, and CEO of Ashvattha Therapeutics Inc. He also serves on the boards of several other organizations, including BIO and Exicure, and holds advisory roles with emerging biotechnology companies.35 His extensive experience encompasses both scientific and financial aspects of the biotechnology industry, making him a valuable asset to any organization he is involved with.1

Contributions and Impact

Dr. Cleland's expertise is particularly focused on the development of next-generation RNA therapeutics, which are pivotal in addressing complex medical challenges. His leadership is expected to significantly influence Elixirgen's strategic direction and technological advancements in the biotech field.14